CSPC Pharmaceutical Group Management

Management Kriterienprüfungen 2/4

CSPC Pharmaceutical Group CEO ist Cuilong Zhang , ernannt in May 2022, hat eine Amtszeit von 2.5 Jahren. Die jährliche Gesamtvergütung beträgt CN¥13.47M , bestehend aus 5.1% Gehalt und 94.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.043% der Aktien des Unternehmens, im Wert von HK$25.35M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.5 Jahre bzw. 7.7 Jahre.

Wichtige Informationen

Cuilong Zhang

Geschäftsführender

CN¥13.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	5.1%
Amtszeit als Geschäftsführer	2.5yrs
Eigentum des Geschäftsführers	0.04%
Durchschnittliche Amtszeit des Managements	2.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.7yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Cuilong Zhang im Vergleich zu den Einnahmen von CSPC Pharmaceutical Group verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	CN¥5b
Jun 30 2024	n/a	n/a	CN¥6b
Mar 31 2024	n/a	n/a	CN¥6b
Dec 31 2023	CN¥13m	CN¥693k	CN¥6b
Sep 30 2023	n/a	n/a	CN¥6b
Jun 30 2023	n/a	n/a	CN¥6b
Mar 31 2023	n/a	n/a	CN¥6b
Dec 31 2022	CN¥11m	CN¥693k	CN¥6b
Sep 30 2022	n/a	n/a	CN¥6b
Jun 30 2022	n/a	n/a	CN¥6b
Mar 31 2022	n/a	n/a	CN¥6b
Dec 31 2021	CN¥9m	CN¥693k	CN¥6b
Sep 30 2021	n/a	n/a	CN¥6b
Jun 30 2021	n/a	n/a	CN¥6b
Mar 31 2021	n/a	n/a	CN¥5b
Dec 31 2020	CN¥9m	CN¥693k	CN¥5b
Sep 30 2020	n/a	n/a	CN¥4b
Jun 30 2020	n/a	n/a	CN¥4b
Mar 31 2020	n/a	n/a	CN¥4b
Dec 31 2019	CN¥7m	CN¥693k	CN¥4b
Sep 30 2019	n/a	n/a	CN¥4b
Jun 30 2019	n/a	n/a	CN¥3b
Mar 31 2019	n/a	n/a	CN¥3b
Dec 31 2018	CN¥4m	CN¥298k	CN¥3b

Vergütung im Vergleich zum Markt: CuilongDie Gesamtvergütung ($USD1.86M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD887.93K).

Entschädigung vs. Einkommen: CuilongDie Bezüge der Mitarbeiter sind um mehr als 20 % gestiegen, während die Unternehmensgewinne im vergangenen Jahr um mehr als 20 % gesunken sind.

Geschäftsführer

Cuilong Zhang (55 yo)

2.5yrs

Amtszeit

CN¥13,472,000

Vergütung

Mr. Cuilong Zhang has been the Vice Chairman of CSPC Pharmaceutical Group Ltd since May 21, 2019 and serves as its Chief Executive Officer since May 27, 2022. He was Rotating Chief Executive Officer of CSP...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Dongchen Cai	Executive Chairman	27.6yrs	CN¥26.68m	24.18% HK$ 14.3b
Cuilong Zhang	Vice-Chairman & CEO	2.5yrs	CN¥13.47m	0.043% HK$ 25.3m
Chunlei Li	Executive Director & Chief Scientist	6.9yrs	CN¥9.42m	0.039% HK$ 22.8m
Weidong Pan	Executive Director	no data	CN¥4.92m	0.013% HK$ 7.6m
Huaiyu Wang	Executive Director	no data	CN¥5.74m	0.013% HK$ 7.6m
Zhenguo Wang	Executive Director	no data	CN¥4.90m	0.013% HK$ 7.6m
Hao Jiang	Executive Director	no data	CN¥4.02m	0.026% HK$ 15.2m
Xin Cai	Group Executive President	no data	keine Daten	keine Daten
Bing Yao	Executive Director	less than a year	keine Daten	keine Daten
Yongjun Liu	Executive president & President of Global Research and Development	less than a year	keine Daten	keine Daten
Tai On Lo	Company Secretary	3.8yrs	keine Daten	keine Daten

2.5yrs

Durchschnittliche Betriebszugehörigkeit

54.5yo

Durchschnittliches Alter

Erfahrenes Management: 1093Das Führungsteam des Unternehmens gilt als erfahren (2.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Dongchen Cai	Executive Chairman	27.6yrs	CN¥26.68m	24.18% HK$ 14.3b
Cuilong Zhang	Vice-Chairman & CEO	6.3yrs	CN¥13.47m	0.043% HK$ 25.3m
Chunlei Li	Executive Director & Chief Scientist	6.9yrs	CN¥9.42m	0.039% HK$ 22.8m
Weidong Pan	Executive Director	18.1yrs	CN¥4.92m	0.013% HK$ 7.6m
Huaiyu Wang	Executive Director	14.1yrs	CN¥5.74m	0.013% HK$ 7.6m
Zhenguo Wang	Executive Director	12.8yrs	CN¥4.90m	0.013% HK$ 7.6m
Hao Jiang	Executive Director	4yrs	CN¥4.02m	0.026% HK$ 15.2m
Xin Cai	Group Executive President	less than a year	keine Daten	keine Daten
Bing Yao	Executive Director	less than a year	keine Daten	keine Daten
Chun Kwok Au	Independent Non-Executive Director	3.8yrs	CN¥340.00k	keine Daten
Bo Wang	Independent Non-Executive Director	11.9yrs	CN¥142.00k	keine Daten
Chuan Chen	Independent Non-Executive Director	8.4yrs	CN¥142.00k	keine Daten

7.7yrs

Durchschnittliche Betriebszugehörigkeit

54.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 1093Die Vorstandsmitglieder gelten als erfahren (7.7 Jahre durchschnittliche Amtszeit).

CSPC Pharmaceutical Group Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Executive Chairman recently bought HK$4.6m worth of stock

Executive Chairman recently bought HK$6.7m worth of stock

CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024

Executive Chairman recently bought HK$13m worth of stock

CSPC Pharmaceutical Group Limited Appoints Li Quan as an Independent Non-Executive Director

CSPC Pharmaceutical Group Announces Resignation of Wu Guizhen as Independent Non-Executive Director

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.065 (vs CN¥0.13 in 3Q 2023)

CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024

Investor sentiment deteriorates as stock falls 15%

Upcoming dividend of HK$0.16 per share

CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023)

CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares.

Executive Chairman recently bought HK$4.6m worth of stock

CSPC Pharmaceutical Group Limited Announces Aprepitant Injection Obtains Drug Registration Approval

Investor sentiment deteriorates as stock falls 17%

Executive Chairman recently bought HK$6.7m worth of stock

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023)

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024

CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval

CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 1Q 2023)

Upcoming dividend of HK$0.14 per share

CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024

CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023

Full year 2023 earnings released: EPS: CN¥0.49 (vs CN¥0.51 in FY 2022)

CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S

CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval

CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings released: EPS: CN¥0.49 (vs CN¥0.51 in FY 2022)

CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024

CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration

CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA

CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets

CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 3Q 2022)

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023

CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE

CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval

Investor sentiment improves as stock rises 19%

CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors

CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA

Upcoming dividend of HK$0.14 per share at 4.7% yield

CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 2Q 2022)

CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023

Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161)

CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023

CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.11 per share at 3.1% yield

First quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 1Q 2022)

CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023

Executive Chairman recently bought HK$13m worth of stock

Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.47 in FY 2021)

CSPC Pharmaceutical Group Limited Announces Highly Selective PRMT5 Inhibitor SYH2045 Obtains Clinical Trial Approval

Cspc Pharmaceutical Group Limited Announces ALMB-0166 for the Treatment of Osteoarthritis Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Receives Approval for SYH2043 from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China